RCKT — Rocket Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $855.35m
- $504.26m
- 40
- 25
- 19
- 17
Annual income statement for Rocket Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 134 | 167 | 224 | 260 | 273 |
| Operating Profit | -134 | -167 | -224 | -260 | -273 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -140 | -169 | -222 | -246 | -259 |
| Net Income After Taxes | -140 | -169 | -222 | -246 | -259 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -140 | -169 | -222 | -246 | -259 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -140 | -169 | -222 | -246 | -259 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.52 | -2.67 | -3.21 | -2.88 | -2.73 |